As the roster of production cars offering quadruple-digit output figures continues to expand and a growing number of ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

Also, Nintendo Switch 2 launches into a changed market where players have come to expect that they will be able to carry their game libraries forward from one machine to another, which precluded a ...

If you had the chance to drive different cars, you may have realised that some cars have their turn signal stalk on the left-hand side, and others on the right-hand side. This small difference could ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn't rise as precipitously, it did improve, gaining 2% to $1 ...

Regeneron’s shares have lost 28.8% in the past year compared with the industry’s decline of 9%. Eylea’s sales in the United States declined 11% year over year to $1.2 billion, primarily due ...

Societe Generale has predicted 2025 will be the best stock picking period in 25 years, citing reflationary policies from President Trump's administration, such as lower taxes, less regulation and ...

In January, that indicator climbed to 57%, the highest since early 2022 and a mere 1 percentage point shy from a sell signal ... allocations unchanged after a 2.8% gain for the S&P 500 SPX ...

Regeneron paid credit card fees to distributors on the condition that distributors did not charge, one of the Company's primary products, Eylea customers more to use a credit card; (2) these ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc ... Revenue was reported as $14.2 billion. This story was generated by Automated Insights (http ...